drugset
drugset / Trial / NCT05352750

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

NCT05352750 ↗

Phase 1 Active not recruiting 42 enrolled Sonnet BioTherapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

Timeline

Start
2022-04-20
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SON-1010 Protein / enzyme biologic — —

Indications

soft tissue sarcoma